Subtype
Cervical Squamous Cell Carcinoma
CI-CAN-00002174Explore in graph →
16 active trials1 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002174Explore in graph →
Clinical trials
82 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer | terminated | Phase 3 | 402 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 |
| completed |
| Phase 1 / Phase 2 |
| 384 |
| National Cancer Institute (NCI)NIH |
| 4 |
| Jul 23, 2019 |
| clinicaltrials |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | completed | Phase 3 | 452 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01295502 | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | unknown | Phase 1 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00064077 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | completed | Phase 3 | 513 | Gynecologic Oncology GroupNETWORK | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02765919 | A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix | completed | Phase 3 | 30 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT02879214 | Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer(Side) | unknown | Phase 2 | 50 | Sichuan Provincial People's HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT00041093 | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00070317 | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer | terminated | N/A | 102 | Gynecologic Oncology GroupNETWORK | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00460356 | Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes | completed | — | 159 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00017004 | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | completed | Phase 3 | 114 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00559377 | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | completed | — | 275 | Gynecologic Oncology GroupNETWORK | 1 | Oct 28, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01639625 | Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application | completed | Phase 2 | 18 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT00389974 | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00499031 | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 1 | Jan 13, 2015 | clinicaltrials |
| NCT00054444 | Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer | completed | Phase 1 | 11 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00104910 | Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | completed | Phase 1 | 64 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00068549 | Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer | completed | Phase 1 | 13 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00031993 | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2019source: clinicaltrials